Risk of infection and duration of protection after the booster dose of the anti-sars-cov-2 vaccine bnt162b2 among healthcare workers in a large teaching hospital in italy: results of an observational study

HIGHLIGHTS

SUMMARY

The high efficacy of mRNA_vaccines in reducing morbidity and mortality from COVID-19 has been demonstrated in both randomised clinical trials and observational studies on real-world scenarios. The Pfizer-BioNTech BNT162b2 mRNA_vaccine proved effective in preventing asymptomatic, symptomatic and severe SARS-CoV-2 infection. Evidence in the scientific literature shows that providing the Pfizer-BioNTech BNT162b2 mRNA_vaccine to HCWs results in significant economic benefits. After extremely low infection rates had been recorded for several months, there was a resurgence of COVID-19 cases from the spring of 2021 onwards, mainly caused by the . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.